{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:37:40Z","timestamp":1788345460950,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11845-022-03131-6","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:02:31Z","timestamp":1661212951000},"page":"1065-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-2815","authenticated-orcid":false,"given":"Caihua","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"issue":"6","key":"3131_CR1","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-20-1088","volume":"30","author":"YN Flores","year":"2021","unstructured":"Flores YN, Datta GD, Yang L et al (2021) Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev 30(6):1193\u20131199","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"3131_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","volume":"15","author":"P Konyn","year":"2021","unstructured":"Konyn P, Ahmed A, Kim D (2021) Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 15(11):1295\u20131307","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3131_CR3","unstructured":"Benson AB, D'Angelica MI, Abbott DE et al (2021) Hepatobiliary cancers, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(5):541\u2013565"},{"key":"3131_CR4","doi-asserted-by":"crossref","unstructured":"Reig M, Forner A, Avila MA et al (2021) Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 156(9):463 e461\u2013463 e430","DOI":"10.1016\/j.medcle.2020.09.004"},{"issue":"2","key":"3131_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","volume":"249","author":"WP Zhou","year":"2009","unstructured":"Zhou WP, Lai EC, Li AJ et al (2009) A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249(2):195\u2013202","journal-title":"Ann Surg"},{"issue":"9","key":"3131_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Zhu Q, Durham J et al (2021) Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer 2(9):891\u2013903","journal-title":"Nat Cancer"},{"issue":"1","key":"3131_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4049\/jimmunol.1400497","volume":"194","author":"K Jaworska","year":"2015","unstructured":"Jaworska K, Ratajczak J, Huang L et al (2015) Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol 194(1):325\u2013333","journal-title":"J Immunol"},{"issue":"5","key":"3131_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.bpg.2014.08.009","volume":"28","author":"B Sangro","year":"2014","unstructured":"Sangro B (2014) Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 28(5):909\u2013919","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3131_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773168","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Xie B, Liu S et al (2021) What happens to the immune microenvironment after PD-1 inhibitor therapy? Front Immunol 12:773168","journal-title":"Front Immunol"},{"issue":"1","key":"3131_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101777","volume":"46","author":"H Xin","year":"2022","unstructured":"Xin H, Zhang C, Ding Z et al (2022) TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports. Clin Res Hepatol Gastroenterol 46(1):101777","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"3131_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","volume":"18","author":"W Lu","year":"2017","unstructured":"Lu W, Jin XL, Yang C et al (2017) Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther 18(6):433\u2013438","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"3131_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.27915","volume":"62","author":"AR Seyal","year":"2015","unstructured":"Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A et al (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62(4):1111\u20131121","journal-title":"Hepatology"},{"issue":"4","key":"3131_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.09.002","volume":"45","author":"L Cai","year":"2021","unstructured":"Cai L, Li H, Guo J et al (2021) Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin Res Hepatol Gastroenterol 45(4):101535","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3131_CR14","doi-asserted-by":"crossref","unstructured":"Li B, Qiu J, Zheng Y et al (2021) Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","DOI":"10.1097\/AS9.0000000000000057"},{"key":"3131_CR15","first-page":"947","volume":"26","author":"W Zhang","year":"2020","unstructured":"Zhang W, Hu B, Han J et al (2020) Preliminary report on the study of conversion therapy of advanced hepatocellular carcinoma combined PD-1 inhibitors with multi-target tyrosine kinase inhibitors. J Chinese J Hepatob Surg 26:947\u2013948","journal-title":"J Chinese Journal of Hepatobiliary Surgery"},{"issue":"1","key":"3131_CR16","doi-asserted-by":"publisher","first-page":"107327481774462","DOI":"10.1177\/1073274817744621","volume":"25","author":"ST Orcutt","year":"2018","unstructured":"Orcutt ST, Anaya DA (2018) Liver resection and surgical strategies for management of primary liver cancer. Cancer Control 25(1):1073274817744621","journal-title":"Cancer Control"},{"issue":"4","key":"3131_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J et al (2020) 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 9(4):452\u2013463","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3131_CR18","doi-asserted-by":"crossref","unstructured":"Vogel A, Martinelli E, clinicalguidelines@esmo.org EGCEa, Committee EG (2021) Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 32(6):801\u2013805","DOI":"10.1016\/j.annonc.2021.02.014"},{"issue":"1","key":"3131_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","volume":"21","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, Cortellini A, Sukumaran A et al (2021) PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 21(1):301","journal-title":"BMC Cancer"},{"issue":"7","key":"3131_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ejso.2006.04.002","volume":"32","author":"A Sasaki","year":"2006","unstructured":"Sasaki A, Iwashita Y, Shibata K et al (2006) Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32(7):773\u2013779","journal-title":"Eur J Surg Oncol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03131-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:16:04Z","timestamp":1686208564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03131-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3131"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03131-6","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board approved the study ethics. All patients signed informed consent before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}